Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (1): 38-44.doi: 10.6040/j.issn.1671-7554.0.2017.1038

Previous Articles    

Effect and mechanism of magnesium isoglycyrrhizinate on the biological behavior of breast cancer cell lines

LI Yi, PENG Jing, ZHANG Lei, LU Jingsong   

  1. Department of Breast Disease, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China
  • Published:2022-09-27

Abstract: Objective To explore the effects and mechanism of magnesium isoglycyrrhizinate on the biological behavior of breast cancer. Methods Breast cell lines MDA-MB-231 and MCF-7 were treated with different concentrations(0, 50, 500 μmol/L)of magnesium isoglycyrrhizinate. Cell proliferation, migration and death were detected by CCK-8 assay, wound healing test, and LDH-cytotoxicity assay kit. Effect of magnesium isoglycyrrhizinate on the expressions of Bax, Bcl-2, Caspase-3, Caspase-9, HSP70 and HSP90 in breast cancer cells were examined by Western blotting. Results After treated with different concentrations of magnesium isoglycyrrhizinate, cell proliferation and migration abilities were inhibited in breast cancer cells, while autophagy and apoptosis increased. The inhibitory effects of platinum on cell migration were enhanced by the combination usage with magnesium isoglycyrrhizinate. Expression of HSP90 was reduced and Bax was promoted in MDA-MB-231 cell line. Expression of HSP70 was reduced in MCF-7 cell line. Conclusion Magnesium isoglycyrrhizinate inhibits the malignant phenotype of human breast cancer cell lines and has the synergic antitumor effect combined with platinum. The mechanism of magnesium isoglycyrrhizinate on MCF-7 and MDA-MB-231 cell lines are different.

Key words: Breast cancer, Magnesium isoglycyrrhizinate, Proliferation, Migration, Apoptosis, MDA-MB-231, MCF-7

CLC Number: 

  • R73-36+1
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
[2] Chen W, Zheng R, Badde PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] Robinson K, Lambiase L, LI J, et al. Fatal cholestatic liver failure associated with gemcitabine therapy[J]. Dig Dis Sci, 2003, 48(9): 1804-1808.
[4] 夏俊.异甘草酸镁在化疗后肝功能异常治疗中的临床应用[J]. 现代中西医结合杂志, 2012, 21(9): 958-959.
[5] 田青, 毕清, 赵明利. 异甘草酸镁治疗化疗药物性肝损害的临床疗效观察 [J]. 中国医药, 2012, 7(5): 588-590. TIAN Qing, BI Qing, ZHAO Mingli. Clinical control study of magnesium isoglycyrrhizinate in the treatment of liver function impairment caused by chemotherapy[J]. China Medicine, 2012, 7(5): 588-590.
[6] 房澍名, 龚新雷, 秦叔逵. 新型甘草酸制剂防治抗肿瘤药物肝损伤的现状和进展[J]. 临床肿瘤学杂志, 2013, 18(9): 833-841. FANG Shuming, GONG Xinlei, QIN Shukui. Current situation and progression of new glycyrrhizin in the prevention and treatment of antineoplastic drug-induced liver injury [J]. Chinese Clinical Oncology, 2013, 18(9): 833-841.
[7] 孙黎, 曹惠明, 沈金芳,等. 静滴异甘草酸镁注射液的人体药代动力学研究 [J]. 中国药理学通报, 2005, 21(11): 1348-1351. SUN Li, CAO Huiming, SHEN Jinfang, et al. Study on the pharmacokinetics of magnesium isoglycyrrhizinate injections in Chinese healthy volunteers[J]. Chinese Pharmacological Bulletin, 2005, 21(11): 1348-1351.
[8] Hibasami H, Iwase H, Yoshioka K, et al. Glycyrrhetic acid(a metabolic substance and aglycon of glycyrrhizin)induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells [J]. Int J Mol Med, 2006, 17(2): 215-219.
[9] Huang RY, Chu YL, Jiang ZB, et al. Glycyrrhizin suppresses lung adenocarcinoma cell growth through inhibition of thromboxane synthase [J]. Cell Physiol Biochem, 2014, 33(2): 375-388.
[10] Kumagai A, Nishino K, Shimomura A, et al. Effect of glycyrrhizin on estrogen action [J]. Endocrinol Jpn, 1967, 14(1): 34-38.
[11] Craig EA, Weissman JS, Horwich AL. Heat shock proteins and molecular chaperones: mediators of protein conformation and turnover in the cell [J]. Cell, 1994, 78(3): 365-372.
[12] Price JT, Quinn JM, Sims NA, et al. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line [J]. Cancer Res, 2005, 65(11): 4929-4938.
[13] Nylandsted J, Brand K, Jäättelä M. Heat shock protein 70 is required for the survival of cancer cells [J]. Ann N Y Acad Sci, 2000, 926: 122-125.
[14] Prasad SJ, Farrand KJ, Matthews SA, et al. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells [J]. J Immunol, 2005, 174(1): 90-98.
[15] Chowdhury S, Veyhl J, Jessa F, et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants[J]. Oncotarget, 2016, 7(22): 32318-32328.
[16] Lin Z, Xu Y, Zhang Y, et al. The prevalence and clinicopathological features of programmed death-ligand 1(PD-L1)expression: a pooled analysis of literatures [J]. Oncotarget, 2016, 7(12): 15033-15046.
[17] Wu P, Wu D, Li L, et al. PD-L1 and survival in solid tumors: a Meta-analysis[J]. PLoS One, 2015, 10(6): e0131403. doi: 10.1371/journal.pone.0131403.
[18] Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small cell lung cancer[J]. Lab Invest, 2014, 94(1): 107-116.
[19] Cierna Z, Mego M, Miskovska V, et al. Prognostic value of programmed-death-1 receptor(PD-1)and its ligand 1(PD-L1)in testicular germ cell tumors[J]. Ann Oncol, 2016, 27(2): 300-305.
[20] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252-264.
[21] Rech AJ, Vonderheide RH. Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment[J]. Cancer Discov, 2013, 3(12): 1330-1332.
[22] Wei H, Wang C, Croce CM, et al. p62/SQSTM1 synergizes with autophagy for tumor growth in vivo [J]. Genes Dev, 2014, 28(11): 1204-1216.
[23] Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success(or failure)[J]. Ann Oncol, 2016, 27(8): 1492-1504.
[24] Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion [J]. Nat Med, 2002, 8(8): 793-800.
[25] Baptista MZ, Sarian LO, Derchain SF, et al. Prognostic significance of PD-L1 and PD-L2 in breast cancer [J]. Hum Pathol, 2016, 47(1): 78-84.
[26] Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death ligand 1(PD-L1)is associated with poor prognosis in human breast cancer[J]. Breast Cancer Res Treat, 2014, 146(1): 15-24.
[1] WANG Xiao-Lei, ZHANG Hai-Thao, ZHANG Hui, GUO Cheng-Hao. Protective effects of shuxuening injecta on vascular  endothelial  cell injury in vitro due to iodine excesses [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 38-.
[2] LU Xiang-Dong, YANG Wei, XU Guang-Meng, QU Yuan-Ming. Expression and role of PPAR-γin meningiomas and troglitazone induced meningiomas cell apoptosis in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 65-.
[3] LIN Yun, XIE Yanqiu. Fertility protection and preservation in breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 42-46.
[4] ZHAO Ge, ZOU Cunhua, SONG Dongdong, ZHAO Shuping. Effects of tanshinone IIA on the proliferation and apoptosis of endometrial carcinoma cells [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 53-58.
[5] ZHANG Zhenwei, LI Jia, CHEN Keming. IGF2BP2/m6A/ITGA5 signal axis regulates the proliferation and migration of renal clear cells [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 74-84.
[6] HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43.
[7] Qifeng YANG,Ning ZHANG. Sentinel lymph node biopsy of breast cancer in the era of precision medicine [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 1-5.
[8] LIU Min, ZHANG Yuchao, MA Xiaoli, LIU Xinyu, SUN Lu, ZUO Dan, LIU Yuantao. Effects of orphan nuclear receptor NR4A1 on H2O2 induced injury of mouse renal podocytes [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 16-21.
[9] SHEN Xiaochang, SUN Yiqing, YAN Lei, ZHAO Xingbo. Expression of aryl hydrocarbon receptor nuclear translocator-like 2 in endometrial cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 74-80.
[10] ZHAO Tingting, QI Yana, ZHANG Ying, YUAN Bing, HAN Mingyong. Mouse breast cancer induces changes of the microenvironment in pre-metastatic lung tissue [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 24-29.
[11] CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30-37.
[12] SONG Tian, FU Linlin, WANG Qiumin, YANG Xiao, WANG Ying, BIAN Yuehong, SHI Yuhua. Expression of fatty acid transport protein 1 in granulosa cells of patients with polycystic ovary syndrome [J]. Journal of Shandong University (Health Sciences), 2022, 60(2): 22-26.
[13] LI Hui, JIANG Chaoyang, LIU Yan, ZHANG Man. Effects and mechanism of histone deacetylase SIRT1 controlled macrophage apoptosis induced by oxidized low density lipoprotein [J]. Journal of Shandong University (Health Sciences), 2022, 60(1): 6-12.
[14] Zhuxiu CHU,Wenjing ZHAO,Xiaoyan LI,Xiaoli KONG,Tingting MA,Liyu JIANG,Qifeng YANG. Significance of neoadjuvant chemotherapy and molecular marker changes in 218 women with breast cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 130-139.
[15] WANG Zhe, LIU Yujie, MAO Qian, GUAN Peixia, BAO Qihan, LI Chengsheng, QIAO Xiaowei, PAN Qingzhong, WANG Suzhen. Evaluation of the efficacy of different regimens for early triple negative breast cancer based on the inverse probability of treatment weighting method [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 113-118.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!